ARA-290 (Cibinetide) for Small Fiber Neuropathy: Targeting the Innate Repair Receptor (IRR) to Heal Nerve Pain

⚡ The 30-Second Fast-Track Summary

• Best For: Small fiber neuropathy (SFN), burning peripheral nerve pain in feet and hands, diabetic neuropathy, sarcoidosis-associated neuropathy, and autonomic nerve dysfunction.
• Mechanism: A 11-amino acid peptide (Cibinetide) derived from erythropoietin (EPO) helix B. It selectively binds the Innate Repair Receptor (IRR / EPOR-CD131), shutting down neuroinflammation and stimulating epidermal nerve fiber re-growth.
• The Breakthrough Difference: Unlike recombinant EPO (which causes dangerous blood thickening, polycythemia, and thrombosis), ARA-290 has zero erythropoietic activity and will not alter red blood cell count or hematocrit.
• Clinical Trial Backing: Evaluated in multiple randomized, double-blind, placebo-controlled Phase II human clinical trials demonstrating verified histological nerve re-innervation.

1. The Agony of Small Fiber Neuropathy (SFN)

Small fiber neuropathy involves damage to the unmyelinated C-fibers and thinly myelinated A-delta nerve fibers that innervate the epidermis and autonomic organs. Patients suffer from intractable burning sensations, hyperalgesia (even bedsheets touching the skin feel excruciating), electric-shock pains, and loss of thermal sensation.

Conventional pharmaceutical treatments (gabapentin, pregabalin, duloxetine) merely numb central pain transmission; they do not heal the damaged nerve fibers or alter disease progression. Over time, skin biopsies reveal a progressive decline in Intraepidermal Nerve Fiber Density (IENFD).

2. Chemical Architecture: The Innate Repair Receptor (IRR)

In the human body, native erythropoietin (EPO) serves two distinct functions mediated by two different receptor complexes:

1. Classical Homodimeric EPO Receptor (EPOR2): Located on bone marrow erythrocyte progenitors. Triggers red blood cell synthesis (erythropoiesis).
2. Heteromeric Innate Repair Receptor (IRR): Composed of one EPO receptor monomer combined with the CD131 (beta-common) receptor subunit. The IRR is silent in healthy tissue but rapidly expressed on neurons, glia, and microvascular endothelium following traumatic or ischemic injury.

Dr. Anthony Cerami (co-discoverer of TNF-alpha) engineered ARA-290 (pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) to specifically mimic the protective spatial helix-B loop of EPO:

• ARA-290 binds selectively to the IRR with high affinity.
• It possesses zero binding affinity for the erythropoietic EPOR2 homodimer.
• As a result, it triggers profound anti-inflammatory, neuroprotective, and regenerative signaling without causing blood clots, stroke, or elevated hematocrit.

3. Human Clinical Trial Evidence for ARA-290

ARA-290 has accumulated extraordinary clinical trial documentation in human patients with severe neuropathic disease:

• Phase IIb Sarcoidosis SFN Trial (Dahan et al., Molecular Medicine): In a double-blind, randomized, placebo-controlled trial, patients with small fiber neuropathy received daily subcutaneous ARA-290 (4 mg) for 28 days. Punch skin biopsies at baseline and Day 28 revealed statistically significant regeneration of intraepidermal nerve fiber density (IENFD), accompanied by dramatic reductions in neuropathic pain scores.
• Diabetic Neuropathy Trials: Clinical trials in patients with Type 2 diabetes demonstrated improved corneal nerve fiber length (evaluated via in vivo corneal confocal microscopy) and enhanced microvascular endothelial blood flow.
• Mechanistic Confirmation: Skin biopsies demonstrated significant downregulation of pro-inflammatory macrophage infiltration (CD68+) and suppression of systemic TNF-alpha and IL-6.

4. Investigative Clinical Dosing & Administration

In clinical trials, ARA-290 is administered via subcutaneous injection as an intensive 4-week to 8-week restorative course.

Clinical Protocol:

• Dosage per Injection: 4 mg (4,000 mcg) administered subcutaneously.
• Frequency: Once daily for 28 to 56 consecutive days (1 to 2 months).
• Timing: Morning subcutaneous injection into abdominal fat using a 31G 5/16" micro-needle.
• Maintenance: Patients achieving histological nerve recovery often transition to a maintenance dose of 4 mg twice weekly.

Volumetric Reconstitution Math:

ARA-290 is typically supplied in 16 mg or 10 mg lyophilized vials:

• For a 16 mg vial: Reconstitute with 4.0 mL of USP bacteriostatic water (concentration = 4.0 mg/mL).
  • A 4 mg clinical dose = 1.0 mL (100 units on a standard U-100 syringe).
• For a 10 mg vial: Reconstitute with 2.5 mL of water (concentration = 4.0 mg/mL).
  • A 4 mg dose = 1.0 mL (100 units).
• Calibrate and verify exact syringe marks in the Helia Reconstitution Calculator.

5. Diagnostic Biomarker Monitoring & Harm Reduction

• Complete Blood Count (CBC) with Hematocrit: While ARA-290 does not stimulate erythropoiesis, auditing CBC confirms stable hemoglobin and rules out underlying nutritional anemias (B12/folate deficiency) that exacerbate neuropathy.
• Comprehensive Metabolic Panel (CMP-14): Confirms baseline renal filtration and hepatic function.
• Hemoglobin A1c (HbA1c): Audits glycemic control, as uncontrolled hyperglycemia continues to injure regenerating small nerve fibers.
• Review Quest and LabCorp diagnostic panels in our Hardware & Labs Directory.

6. Safety & Adverse Events Profile

Across Phase II clinical trials involving hundreds of patients, ARA-290 demonstrated an exceptional safety and tolerability profile:

• Adverse Event Rate: Comparable to placebo.
• Zero Thrombotic Events: No changes observed in platelet count, hematocrit, or blood viscosity.

👉 Calibrate Your Neuro-Recovery Protocol in the Wizard ➔